On Monday 10 March, the Secretary of State for Health, Jeremy Hunt, tabled a number of amendments to the Care Bill. These relate to the release of data by the Health and Social Care Information Centre (HSCIC) and include amendments to the Health and Social Care Act 2012, which established the HSCIC.

 

In response to the Care Bill amendments, the ABPI has highlighted its position on the use of electronic health data.

​“Linking electronic health records through initiatives such as care.data will supply information for medical research that will allow a better understanding of the diseases we are developing medicines for.

“It will help ensure faster development of new innovative medicines that will help us to work towards the prevention and cure of life threatening diseases, and ultimately transform health outcomes in the UK. Through responsible data sharing, we can bring leading-edge treatments and technologies to patients, and re-establish the UK as a global leader in the life sciences.

“It is crucial to have strict safeguards in place to protect patient confidentiality and we are supportive of strong governance and safeguarding procedures in order to protect patient confidentiality whenever engaging in electronic record data sharing. The pharmaceutical industry has long been accustomed to safeguarding and protecting patient confidentiality for participants involved in clinical research and through the well-established Clinical Practice Research Datalink (CPRD).”

Media enquiries

ABPI Press Office

Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441

Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811 Email: pressoffice@abpi.org.uk

Notes to editors

The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.

The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.

 
 
Print this page icon Print this page
 
Please choose the subject of your enquiry from the list below:
 
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.